Domantis lung study nets 'exciting' results
27 October, 2005 by Graeme O'NeillUK human domain-antibody (dAb) developer Domantis has reported spectacular success in trial of an inhaled anti-inflammatory dAB in an in vivo model of chronic obstructive pulmonary disorder (COPD).
Phylogica and Sunshine Heart net grants
26 October, 2005 by Helen SchullerDrug developer Phylogica (ASX:PYC) and artificial heart company Sunshine Heart (ASX:SHC) have been awarded a Commercial Ready grants from AusIndustry, worth $2.27 million and $2.223 million respectively.
Monash team determines cancer protein form
25 October, 2005 by Graeme O'NeillMonash University researchers have determined the structure of a key oncoprotein, JAK2, being targeted by Melbourne oncology drug developer Cytopia (ASX:CYT).
Phospha E linked to healthy cardiovascular function
21 October, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has found its vitamin product Phospha E has reduced LDL-C (bad cholesterol) concentrations in blood by up to 44 per cent in an animal study.
Apollo starts psoriasis trial
20 October, 2005 by Helen SchullerSydney-based biopharma Apollo Life Sciences (ASX:AOP) has commenced its phase Ib clinical trial for a topical psoriasis treatment, developed from human-expressed protein.
Panvax signs agreement with US institute to develop malaria vaccine
18 October, 2005 by Graeme O'NeillMelbourne's Austin Research Institute (ARI) and vaccine developer Panvax have signed an agreement with the Walter Reed Army Institute of Research to develop an experimental malaria vaccine.
Plantigens: best prospect for defeating Malaria?
17 October, 2005 by Graeme O'NeillAustralian malaria vaccine researcher Professor Ross Coppell says smallpox was eradicated from the planet because the mass vaccination campaign employed a powdered formulation of dried, attenuated virus.
Norwood to commence phase II cancer vaccine trial
13 October, 2005 by Helen SchullerMelbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed an agreement for a phase II collaboration with the University of Texas MD Anderson Cancer Centre of Houston to determine whether its investigational melanoma cancer vaccine generates an enhanced immune response.
Prozac prevents onset of Huntington's disease in mice
13 October, 2005 by Graeme O'NeillA collaborative study by Australian and UK neuroscientists has shown that the anti-depressant fluoxetine (Prozac) prevents the onset of Huntington's disease (HD) in transgenic HD mice.
Avantogen cancer gene test partnership progressing
10 October, 2005 by Ruth BeranA partnership initiated in 2003 between Avantogen (ASX:ACU) (formerly Australian Cancer Technology) and Prof Ursula Kees at Perth's Telethon Institute for Child Health Research is closer to developing a diagnostic test to enable more effective treatment of cancer.
Prima Biomed sells anti-inflammatory program
06 October, 2005 by Helen SchullerPrima Biomed (ASX: PRR) has entered into an agreement to sell all the assets of its subsidiary Arthron to Toronto-based private company Trillium Therapeutics.
Antisense 'proof-of-concept' study demonstrates activity of ATL1101 in psoriasis patients
05 October, 2005 by Helen SchullerAntisense Therapeutics (ASX:ANP) has produced positive results from a 'proof-of-concept' study of its second generation antisense drug ATL1101 to suppress the insulin-like growth factor-1 receptor (IGF-1R), which is under development as a cream for the topical treatment of the skin disorder psoriasis.
Citrofresh quashes HIV orange cure talk
29 September, 2005 by Staff WritersGeelong-based disinfectant maker Citrofresh International (ASX:CTF), which caused a stock frenzy with news of a cure-all ingredient found in oranges, has dashed investors' hopes it had a vaccine against HIV, SARS, flu and the common cold.
Acrux granted four US patents, licensee meets with FDA
27 September, 2005 by Ruth BeranAcrux (ASX:ACR) has been granted four more US patents relating to its transdermal drug delivery technology.
Phosphagenics claims promising insulin results
21 September, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH) has successfully delivered insulin through the skin of animals using its patented transdermal drug delivery system TPM-01.
